Johnson & Johnson Reports Phase 3 extension Data for Tepotinib in Neuromyelitis optica spectrum disorder

Johnson & Johnson today announced Phase 3 extension results for Tepotinib in patients with Neuromyelitis optica spectrum disorder. The study demonstrated that Tepotinib demonstrates favorable safety profile compared to standard of care or placebo. These results provide important insights into the treatment of Neuromyelitis optica spectrum disorder and support the continued development of Tepotinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results. The safety profile of Tepotinib was consistent with previous observations, with no new safety signals identified.